Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Anal Cancer Metastatic × atezolizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 11 Small Cell Lung Carcinoma 6 Lung Neoplasms 6 Carcinoma, Hepatocellular 6 Breast Neoplasms 6 Urinary Bladder Neoplasms 5 Carcinoma, Transitional Cell 5 Triple Negative Breast Neoplasms 4 Ovarian Neoplasms 4 Neoplasms 4 Neoplasm Metastasis 4 Melanoma 4 Glioblastoma 4 Advanced Solid Tumor 4 Stomach Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Solid Cancer 2 Small Cell Lung Cancer Extensive Stage 2 Sarcoma 2 Recurrence 2 Prostatic Neoplasms 2 Pancreatic Neoplasms 2 Lymphoma, Non-Hodgkin 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma, Follicular 2 Leukemia, Myeloid, Acute 2 Gliosarcoma 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Renal Cell 2

Interventions

trifluridine tipiracil drug combination 1 reolysin 1 atezolizumab 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07280377 2025-12-12

GOBLET

Oncolytics Biotech

Phase 1/2 Recruiting

Gastrointestinal

Anal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡